Beam Therapeutics annual book value per share
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Book Value Per Share Growth & History (BEAM)
Beam Therapeutics's book value per share was $12.17 for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.17 | $3.40 | +38.76% |
| 2024 | 2024-12-31 | $8.77 | -$3.25 | −27.04% |
| 2023 | 2023-12-31 | $12.02 | $1.73 | +16.82% |
| 2022 | 2022-12-31 | $10.29 | -$1.80 | −14.88% |
| 2021 | 2021-12-31 | $12.09 | $7.80 | +181.86% |
| 2020 | 2020-12-31 | $4.29 | $31.74 | — |
| 2019 | 2019-12-31 | -$27.45 | — | — |
Beam Therapeutics quarterly book value per share
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.34 | -$0.12 | −1.12% |
| Q1 2026 | 2026-03-31 | $11.33 | $0.10 | +0.90% |
| Q4 2025 | 2025-12-31 | $12.17 | $3.40 | +38.76% |
| Q3 2025 | 2025-09-30 | $9.53 | -$0.05 | −0.57% |
| Q2 2025 | 2025-06-30 | $10.45 | $0.09 | +0.84% |
| Q1 2025 | 2025-03-31 | $11.23 | $0.13 | +1.17% |
| Q4 2024 | 2024-12-31 | $8.77 | -$3.25 | −27.04% |
| Q3 2024 | 2024-09-30 | $9.58 | -$0.23 | −2.32% |
| Q2 2024 | 2024-06-30 | $10.37 | -$0.04 | −0.43% |
| Q1 2024 | 2024-03-31 | $11.10 | $0.87 | +8.52% |
| Q4 2023 | 2023-12-31 | $12.02 | $1.73 | +16.82% |
| Q3 2023 | 2023-09-30 | $9.81 | -$0.33 | −3.23% |
| Q2 2023 | 2023-06-30 | $10.41 | -$0.97 | −8.51% |
| Q1 2023 | 2023-03-31 | $10.23 | -$1.66 | −13.93% |
| Q4 2022 | 2022-12-31 | $10.29 | -$1.80 | −14.88% |
| Q3 2022 | 2022-09-30 | $10.14 | -$2.46 | −19.55% |
| Q2 2022 | 2022-06-30 | $11.38 | $2.87 | +33.71% |
| Q1 2022 | 2022-03-31 | $11.89 | $5.04 | +73.70% |
| Q4 2021 | 2021-12-31 | $12.09 | $7.80 | +181.86% |
| Q3 2021 | 2021-09-30 | $12.61 | $8.64 | +217.79% |
| Q2 2021 | 2021-06-30 | $8.51 | $3.86 | +83.05% |
| Q1 2021 | 2021-03-31 | $6.84 | $1.52 | +28.47% |
| Q4 2020 | 2020-12-31 | $4.29 | $31.74 | — |
| Q3 2020 | 2020-09-30 | $3.97 | — | — |
| Q2 2020 | 2020-06-30 | $4.65 | — | — |
| Q1 2020 | 2020-03-31 | $5.33 | — | — |
| Q4 2019 | 2019-12-31 | -$27.45 | — | — |
Beam Therapeutics book value per share trends
Over the last five fiscal years, Beam Therapeutics's book value per share increased from $4.29 to $12.17, a change of $7.88. The latest reported quarter, Q2 2026, shows $10.34.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...